Lilly vs Pfizer: Obesity Race Reaches Market Highs
Lilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
This piece breaks down why Total Market Return 2024 matters, highlighting drivers, risks, and practical steps to align holdings with your goals.
28,491 articlesLilly leads the GLP-1 obesity wave as Pfizer rebuilds with deals and repurposed assets. Q1 2026 results underscore tw...
SK Hynix kicked off trading on Wall Street with a double-digit rally, marking the largest U.S. IPO by a foreign compa...
Long-term investors chase multibagger dreams. This article explores a high-potential biotech setup with 26 late-stage...
A seasoned fund boosted its stake in ZoomInfo, revealing a confident bet on GTM's growth story. This article explains...
As traditional markets wobble, smart investors are turning to carefully chosen cryptocurrencies. This guide reveals t...
Lucid represents a high-risk, high-reward bet in the EV space. Before you consider investing, these three practical f...
Broadcom is slated to report fiscal Q2 results after the market closes today, with investors focusing on AI-driven re...
A Perdoceo director recently exercised 9,308 options and sold shares, triggering questions for investors. This guide ...
Two popular short-term corporate bond ETFs share many similarities, but subtle differences can matter for your portfo...
As Vanguard S&P 500 ETF continues to grow wealth for long-term investors, retirees weigh its 1.1% yield against highe...
BlackRock launches a new staked Ethereum trust on Nasdaq, combining price upside with validator yields. The move mark...
As signs point to a softer economy in 2026, dividend-focused ETFs can provide ballast. This guide identifies three re...